Home / Companies / Zydus Cadila Q4 net profit up 46%

Ahmedabad: Drugmaker Cadila Healthcare Ltd, also known as Zydus Cadila, posted a 46% increase in net profit for the quarter ended 31 March as it increased sales and paid less in interest charges.

Net profit rose to 350 crore in the three months from 239 crore a year earlier, on an 18% rise in gross sales to 2,297 crore from 1,952 crore.

For the full year to 31 March, Zydus Cadila registered a net profit of 1,151 crore, up 43% from 804 crore. In the year, the company registered gross sales of 8,658 crore, up 20% from 7,208 crore in the previous year on a consolidated basis.

During the year, the group launched Exemptia, the world’s first biosimilar for adalimumab, a drug used for reducing the signs and symptoms of rheumatoid arthritis. The group also launched SoviHep, a therapy for Hepatitis C, in alliance with Gilead Sciences Inc.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Recommended For You
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsFeedbackRedeem a Gift CardLogout